Boston Common Asset Management, LLC Amgen Inc Transaction History

Boston Common Asset Management, LLC

$1.76 Billion
Q2 2025

A detailed history of Boston Common Asset Management, LLC transactions in Amgen Inc stock. As of the latest transaction made, Boston Common Asset Management, LLC holds 47,460 shares of AMGN stock, worth $13.5 Million. This represents 0.75% of its overall portfolio holdings.

Number of Shares

47,460

Previous 49,715 4.54%

Holding current value

$13.5 Million

Previous $15.5 Million 14.44%

% of portfolio

0.75%

Previous 0.91%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 22, 2025	SELL	$262.28 - $309.85 $591,441 - $698,711	-2,255 Reduced 4.54%	47,460 $13.3 Million
Q1 2025 Apr 03, 2025	BUY	$258.59 - $327.36 $7.24 Million - $9.17 Million	28,004 Added 128.99%	49,715 $15.5 Million
Q4 2024 Jan 15, 2025	BUY	$258.78 - $328.31 $5.44 Million - $6.9 Million	21,024 Added 3060.26%	21,711 $5.66 Million
Q2 2024 Jul 08, 2024	SELL	$262.75 - $319.31 $3.56 Million - $4.32 Million	-13,531 Reduced 95.17%	687 $215,000
Q1 2024 Apr 11, 2024	SELL	$268.87 - $324.56 $3.96 Million - $4.78 Million	-14,728 Reduced 50.88%	14,218 $4.04 Million
Q4 2023 Jan 09, 2024	SELL	$255.7 - $288.46 $4.52 Million - $5.1 Million	-17,666 Reduced 37.9%	28,946 $8.34 Million
Q3 2023 Oct 11, 2023	SELL	$218.65 - $271.46 $3.53 Million - $4.38 Million	-16,140 Reduced 25.72%	46,612 $12.5 Million
Q2 2023 Jul 24, 2023	SELL	$214.27 - $253.37 $3.68 Million - $4.36 Million	-17,193 Reduced 21.51%	62,752 $13.9 Million
Q1 2023 May 17, 2023	SELL	$225.79 - $275.2 $628,825 - $766,432	-2,785 Reduced 3.37%	79,945 $19.3 Million
Q4 2022 Jan 26, 2023	SELL	$229.03 - $291.01 $3.72 Million - $4.73 Million	-16,244 Reduced 16.41%	82,730 $21.7 Million
Q3 2022 Oct 20, 2022	BUY	$224.46 - $253.15 $1.2 Million - $1.35 Million	5,332 Added 5.69%	98,974 $22.3 Million
Q2 2022 Aug 10, 2022	BUY	$230.71 - $256.74 $4.34 Million - $4.83 Million	18,810 Added 25.14%	93,642 $22.8 Million
Q1 2022 May 16, 2022	BUY	$219.27 - $242.57 $4.8 Million - $5.31 Million	21,883 Added 41.33%	74,832 $18.1 Million
Q4 2021 Jan 31, 2022	BUY	$198.88 - $227.6 $195,101 - $223,275	981 Added 1.89%	52,949 $11.9 Million
Q3 2021 Nov 12, 2021	BUY	$212.27 - $248.7 $59,011 - $69,138	278 Added 0.54%	51,968 $11.1 Million
Q2 2021 Aug 19, 2021	SELL	$233.58 - $259.14 $493,320 - $547,303	-2,112 Reduced 3.93%	51,690 $12.6 Million
Q1 2021 May 14, 2021	SELL	$221.91 - $258.6 $138,028 - $160,849	-622 Reduced 1.14%	53,802 $13.4 Million
Q4 2020 Feb 05, 2021	BUY	$216.38 - $257.67 $3.04 Million - $3.63 Million	14,071 Added 34.87%	54,424 $12.5 Million
Q3 2020 Nov 10, 2020	BUY	$234.65 - $260.95 $1.12 Million - $1.25 Million	4,776 Added 13.42%	40,353 $10.3 Million
Q2 2020 Aug 10, 2020	BUY	$197.81 - $242.74 $290,187 - $356,099	1,467 Added 4.3%	35,577 $8.39 Million
Q1 2020 May 08, 2020	BUY	$182.24 - $241.7 $49,022 - $65,017	269 Added 0.79%	34,110 $6.92 Million
Q4 2019 Jan 28, 2020	SELL	$189.21 - $243.2 $26,678 - $34,291	-141 Reduced 0.41%	33,841 $8.16 Million
Q3 2019 Nov 07, 2019	BUY	$174.11 - $208.62 $4.12 Million - $4.94 Million	23,663 Added 229.31%	33,982 $6.58 Million
Q2 2019 Jul 26, 2019	SELL	$166.7 - $195.41 $80,849 - $94,773	-485 Reduced 4.49%	10,319 $1.9 Million
Q1 2019 May 03, 2019	SELL	$180.87 - $203.88 $33,460 - $37,717	-185 Reduced 1.68%	10,804 $2.05 Million
Q4 2018 Jan 25, 2019	SELL	$178.4 - $208.25 $8,028 - $9,371	-45 Reduced 0.41%	10,989 $2.14 Million
Q3 2018 Nov 01, 2018	SELL	$185.29 - $208.89 $525,482 - $592,412	-2,836 Reduced 20.45%	11,034 $2.29 Million
Q2 2018 Aug 06, 2018	BUY	$166.05 - $186.51 $392,708 - $441,096	2,365 Added 20.56%	13,870 $2.56 Million
Q1 2018 Apr 26, 2018	BUY	$169.43 - $198.0 $1.95 Million - $2.28 Million	11,505 New	11,505 $1.96 Million

Others Institutions Holding AMGN

# of Institutions

3,283

Shares Held

427M

Call Options Held

7.34M

Put Options Held

7.43M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $152B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Common Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boston Common Asset Management, LLC with notifications on news.

Account

Boston Common Asset Management, LLC Amgen Inc Transaction History